Willem J. A. Witlox

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen, G. Worthy, M. Joore, 2019, PharmacoEconomics.

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen, G. Worthy, M. Joore, 2019, PharmacoEconomics.

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen, G. Worthy, S. Duffy, 2020, PharmacoEconomics.

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen, G. Worthy, M. Joore, 2022, PharmacoEconomics.

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

M. Hiligsmann, J. Kleijnen, S. Duffy, 2021, PharmacoEconomics.

Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

J. Kleijnen, M. Westwood, G. Worthy, 2020, PharmacoEconomics.

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective

C. Noake, Robert Wolff, Willem J. A. Witlox, 2024, PharmacoEconomics.